ArQule (ARQL) to Present Clinical Data for its BTK Inhibitor ARQ 531 at EHA

June 7, 2019 7:03 AM

ArQule, Inc. (Nasdaq: ARQL), today announced that it will present clinical data from the company-sponsored phase 1 dose escalation study ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found